The in-vitro activity of ceftazidime against clinically important pathogens

Area of Science:

• Medical Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Antimicrobial resistance is a growing global health concern.
• Cephalosporins are a critical class of antibiotics used to treat bacterial infections.
• Evaluating the in-vitro activity of new cephalosporins is essential for guiding clinical practice.

Purpose of the Study:

• To assess the in-vitro antimicrobial activity of ceftazidime.
• To compare ceftazidime's efficacy against other cephalosporins.
• To determine ceftazidime's spectrum of activity against clinical isolates.

Main Methods:

• Broth dilution method was employed for antimicrobial susceptibility testing.
• 1414 Gram-negative bacilli and 250 Gram-positive cocci clinical isolates were tested.
• Isolates were sourced from 26 hospitals in the Rhein-Main area.

Main Results:

• Ceftazidime showed in-vitro activity against Enterobacteriaceae comparable to cefotaxime and moxalactam.
• Ceftazidime exhibited enhanced activity against Acinetobacter species.
• High activity was observed against both sensitive and resistant strains of Pseudomonas aeruginosa and Haemophilus influenzae.
• Limited activity was noted against Staphylococcus aureus; inactivity against Streptococcus faecalis.

Conclusions:

• Ceftazidime possesses a broad spectrum of activity, particularly against key Gram-negative pathogens.
• Its efficacy against Pseudomonas aeruginosa and Haemophilus influenzae is notable.
• Ceftazidime's utility against Gram-positive cocci is restricted, consistent with other cephalosporins.